Transposon Therapeutics, Inc. is investigating the safety and tolerability of TPN-101, an oral medication, in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) associated with a mutation in the C9orf72 gene. Eligible participants have a 60% chance of receiving TPN-101 and a 40% chance of receiving placebo (sugar pill) during the 24-week double-blind treatment period and a 100% chance of receiving TPN-101 during the subsequent 24-week open-label treatment period. 

---

To be eligible for this 58-week (1.1 year) study, you must:

1. Have the C9orf72 mutation as confirmed by clinical genetic testing  
2. Have a caregiver/study partner accompany you at all visits
3. Be on stable doses of all other medications for 1 month prior to screening
4. Be diagnosed with ALS and/or FTD